## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Time Reported: 11/15/2024 04:15 AM

UTC

Quest

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Source:

ORDERING PHYSICIAN:

## Joshua A Emdur,

D.O.

600 Congress Avenue

Floor 14

Austin, TX, 78701

	Lab Ref #:	773650				
Test		n Range	Out Of Rar	nge	Reference Range	Lab
IRON, TIBC AND FERRITIN PANEL	Collected: 1	1/06/2024 03:32 F	PM UTC Red	ceived: 11/	06/2024 03:34 PM UT	С
IRON, TOTAL		52			50-180 mcg/dL	UL
IRON BINDING CAPACITY		320			250-425 mcg/dL (calc)	UL
% SATURATION				<u>16</u> L	20-48 % (calc)	UL
FERRITIN		160			38-380 ng/mL	UL
LIPOPROTEIN (a) Collected: 11/0	6/2024 03:32 PI	M UTC Receive	ed: 11/06/2024	03:34 PM	UTC	
LIPOPROTEIN (a)		61			nmol/L	EN
Reference Range <	75					
Risk:						
Optimal <	75					
	5-125					
High >	125					
Cardiovascular eve	nt risk cate	gorv				
cut points (optima						
are based on Tsimil	ka S. JACC					
2017;69:692-711.						
URIC ACID Collected: 11/06/2024	03:32 PM UTC	Received: 11/0	06/2024 03:34	PM UTC		
URIC ACID		5.0			4.0-8.0 mg/dL	UL
Therapeutic target for	or gout pati	ents: <6.0 mg	g/dL		-	
COMPREHENSIVE METABOLIC P	ANEL Collecte	ed: 11/06/2024 03	3:32 PM UTC	Received	d: 11/06/2024 03:34 P	М

Therapeutic target for go	out patients: <6.0 mg/dL		
COMPREHENSIVE METABOLIC PANEL UTC	Collected: 11/06/2024 03:32 PM UTC	Received: 11/06/2024 03:34 PM	1
GLUCOSE	99	65-99 mg/dL	UL
Fasting refere	ence interval		
UREA NITROGEN (BUN)	25	7-25 mg/dL	UL
CREATININE	1.02	0.60-1.29 mg/dL	UL
EGFR	94	> OR = 60 mL/min/1.	UL
		73m2	
BUN/CREATININE RATIO	SEE NOTE:	6-22 (calc)	UL
Not Reported: BUN and reference range.	Creatinine are within	, ,	
SODIUM	140	135-146 mmol/L	UL
POTASSIUM	4.5	3.5-5.3 mmol/L	UL
CHLORIDE	103	98-110 mmol/L	UL
CARBON DIOXIDE	31	20-32 mmol/L	UL
CALCIUM	9.3	8.6-10.3 mg/dL	UL



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Source:

**Lab Ref #:** 773650

ORDERING PHYSICIAN:

# Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab
PROTEIN, TOTAL	6.9		6.1-8.1 g/dL	UL
ALBUMIN	4.6		3.6-5.1 g/dL	UL
GLOBULIN	2.3		1.9-3.7 g/dL (calc)	UL
ALBUMIN/GLOBULIN RATIO	2.0		1.0-2.5 (calc)	UL
BILIRUBIN, TOTAL	0.4		0.2-1.2 mg/dL	UL
ALKALINE PHOSPHATASE	44		36-130 U/L	UL
AST	24		10-40 U/L	UL
ALT	25		9-46 U/L	UL

ALBUMIN, RANDOM URINE W/O CREATININE Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

ALBUMIN, URINE 0.5 See Note: mg/dL

Reference Range:

Reference Range Not established

RAM

The ADA defines abnormalities in albumin excretion as follows:

Albuminuria Category Result (mg/g creatinine)

Normal to Mildly increased <30 Moderately increased 30-299 Severely increased > OR = 300

The ADA recommends that at least two of three specimens collected within a 3-6 month period be abnormal before considering a patient to be within a diagnostic category.

URINALYSIS, COMPLETE	Collected: 11/06/2024 03:32 PM UTC	Received: 11/06/2024 03:34 PM UTC	
COLOR	YELLOW	YELLOW	UL
APPEARANCE	CLEAR	CLEAR	UL
SPECIFIC GRAVITY	1.021	1.001-1.035	UL
PH	6.0	5.0-8.0	UL
GLUCOSE	NEGATIVE	NEGATIVE	UL
BILIRUBIN	NEGATIVE	NEGATIVE	UL
KETONES	NEGATIVE	NEGATIVE	UL
OCCULT BLOOD	NEGATIVE	NEGATIVE	UL
PROTEIN	NEGATIVE	NEGATIVE	UL
NITRITE	NEGATIVE	NEGATIVE	UL
LEUKOCYTE ESTERASE	NEGATIVE	NEGATIVE	UL
WBC	NONE SEEN	< OR = 5 /HPF	UL
RBC	NONE SEEN	< OR = 2 /HPF	UL



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

The contents of this document and/or fax transmission are intended only for the use of the individual or entity to which they are addressed and may contain information that is legally privileged, confidential and exempt from disclosure, including protected health information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. If you have received or obtained this document or fax transmission in error, please notify the original sender or contact Health Gorilla Inc. at 1-844-446-7455 immediately by telephone or by email at privacy@healthgorilla.com and delete this document immediately.

UL

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843

STATUS: Final

Source: Quest 11/15/2024 04:15 AM **Time Reported:** 

UTC

11/15/2024 04:19 AM Received:

UTC

Accession SZ983211Q

Number:

Lab Ref #: 773650 ORDERING PHYSICIAN:

# Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 /HPF	UL
BACTERIA	NONE SEEN		NONE SEEN /HPF	UL
HYALINE CAST	NONE SEEN		NONE SEEN /LPF	UL
NOTE				UL

This urine was analyzed for the presence of WBC, RBC, bacteria, casts, and other formed elements. Only those elements seen were reported.

	0 II			
,		eceived: 11/06/202	4 03:34 PM UTC	
WHITE BLOOD CELL COUNT	Γ 5.3		3.8-10.8 Thousand	UL
			/uL	
RED BLOOD CELL COUNT	4.62		4.20-5.80 Million/uL	UL
HEMOGLOBIN		<u>12.7</u> L	13.2-17.1 g/dL	UL
HEMATOCRIT	39.9		38.5-50.0 %	UL
MCV	86.4		80.0-100.0 fL	UL
MCH	27.5		27.0-33.0 pg	UL
MCHC		<u>31.8</u> L	32.0-36.0 g/dL	UL
For adults, a sli	ight decrease in the calculated I		Ŭ	
value (in the rar	nge of 30 to 32 $g/dL$ ) is most li	kely		
not clinically si	ignificant; however, it should be	e		
interpreted with	caution in correlation with other	er		
<del>-</del>	ers and the patient's clinical			
condition.				
RDW	12.7		11.0-15.0 %	UL
PLATELET COUNT	184		140-400 Thousand	UL
			/uL	
MPV	10.6		7.5-12.5 fL	UL
ABSOLUTE NEUTROPHILS	2873		1500-7800 cells/uL	UL
ABSOLUTE LYMPHOCYTES	1701		850-3900 cells/uL	UL
ABSOLUTE MONOCYTES	429		200-950 cells/uL	UL
ABSOLUTE EOSINOPHILS	249		15-500 cells/uL	UL
ABSOLUTE BASOPHILS	48		0-200 cells/uL	UL
NEUTROPHILS	54.2		%	UL
LYMPHOCYTES	32.1		%	UL
MONOCYTES	8.1		%	UL
EOSINOPHILS	4.7		%	UL
BASOPHILS	0.9		%	UL

**HS CRP** Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

**HS CRP** < 0.2 mg/L

Reference Range Optimal <1.0

Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.

For ages >17 Years:



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

The contents of this document and/or fax transmission are intended only for the use of the individual or entity to which they are addressed and may contain information that is legally privileged, confidential and exempt from disclosure, including protected health information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. If you have received or obtained this document or fax transmission in error, please notify the original sender or contact Health Gorilla Inc. at 1-844-446-7455 immediately by telephone or by email at privacy@healthgorilla.com and delete this document immediately.

UL

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843

#### STATUS: Final

Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Source:

**Lab Ref #:** 773650

ORDERING PHYSICIAN:

# Joshua A Emdur,

D.O.

600 Congress Avenue Floor 14

Austin, TX, 78701

Test		In Range	Out Of Range	Reference Range	Lab
	hs-CRP mg/L	Risk According to AHA/CDC Guide	elines		
	<1.0	Lower relative cardiovascular	risk.		
	1.0-3.0	Average relative cardiovascular	risk.		
	3.1-10.0	Higher relative cardiovascular	risk.		
		Consider retesting in 1 to 2 we	eeks to		
		exclude a benign transient elev	vation		
		in the baseline CRP value secon	ndary		
		to infection or inflammation.	-		
	>10.0	Persistent elevation, upon rete	esting,		
		may be associated with infection	_		
		inflammation.			

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3): 499-511.

CORTISOL, TOTAL, LC/MS Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

CORTISOL, TOTAL, LC/MS

13.8

mcg/dL

EZ

Adult Reference Ranges for Cortisol, Total:

8-10 AM 4.6-20.6 mcg/dL 4-6 PM 1.8-13.6 mcg/dL

Cortisol Response to ACTH

Peak >20.0 mcg/dL

Peak >16.0 mcg/dL after IM injection

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

#### INSULIN Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

INSULIN 3.8 uIU/mL EN

Reference Range < or = 18.4

Risk:

Optimal < or = 18.4

Moderate NA High >18.4



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Source: Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Lab Ref #: 773650

ORDERING PHYSICIAN:

## Joshua A Emdur,

D.O.

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test In Range Out Of Range Reference Range Lab

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Insulin Reference Interval studies performed at Quest Diagnostics in 2022.

T4, FREE Collected: 11/06/2	024 03:32 PM UTC Received: 11/06/202	24 03:34 PM UTC
T4, FREE	1.1	0.8-1.8 ng/dL
TSH Collected: 11/06/2024 0	3:32 PM UTC Received: 11/06/2024 03:	34 PM UTC
TSH	2.13	0.40-4.50 mIU/L
<b>T3, FREE</b> Collected: 11/06/2	024 03:32 PM UTC Received: 11/06/202	24 03:34 PM UTC
T3, FREE	3.3	2.3-4.2 pg/mL <sup>UI</sup>
VITAMIN D,25-OH,TOTAL,IA	Collected: 11/06/2024 03:32 PM UTC	Received: 11/06/2024 03:34 PM UTC
VITAMIN D,25-OH,TOTAL,IA	30	30-100 ng/mL

VITAMIN D,25-OH,TOTAL,IA

Vitamin D Status

25-OH Vitamin D:

Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

See Note 1

#### APOLIPOPROTEIN B Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

APOLIPOPROTEIN B 85 mg/dL EN

Reference Range < 90

Risk Category:

Optimal <90
Moderate 90-119
High > or = 120

Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid

Association recommendations-Jacobson

HEALTH GORILLA

Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Source:

**Lab Ref #:** 773650

ORDERING PHYSICIAN:

# Joshua A Emdur,

D.O.

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test In Range Out Of Range Reference Range Lab

TA et al. J of Clin Lipid. 2015; 9: 129-169 and Jellinger PS et al. Endocr Pract. 2017;23(Suppl 2):1-87.

HEMOGLOBIN A1c Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

**HEMOGLOBIN A1c** 

5.5

<5.7 % of total Hgb

UL

For the purpose of screening for the presence of diabetes:

> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin Alc <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

MERCURY, BLOOD Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

MERCURY, BLOOD

See Note 2

4

<OR=10 mcg/L

EN

Note 1

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/educational purposes only.)

Note 2

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

ABO GROUP AND RH TYPE Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Source:

**Lab Ref #:** 773650

ORDERING PHYSICIAN:

# Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab
ABO GROUP	A			UL
RH TYPE	RH(D) POSITIVE			UL

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ111 (This link is being provided for informational/educational purposes only.)

MAGNESIUM, RBC Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

MAGNESIUM, RBC 4.9 4.0-6.4 mg/dL Z3E

(Note)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

MDF med fusion 2501 South State Highway 121,Suite 1100 Lewisville TX 75067 972-966-7300 Ithiel James L. Frame, MD, PhD

LIPOPROTEIN FRACTIONATION ION MOBILITY Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03: 34 PM UTC

34 PM UTC			
LDI PARTICI E NUMBER	1643 H	<1138 nmol/l	Z4M

Relative Risk: Optimal <1138; Moderate 1138-1409; High >1409. Male and Female Reference Range: 1016 to 2185 nmol/L.

LDL SMALL 316 H <142 nmol/L Z4M

Relative Risk: Optimal <142; Moderate 142-219; High >219. Male Reference Range: 123 to 441 nmol/L; Female Reference Range: 115 to 386 nmol/L.

Range: 115 to 386 nmol/L. **LDL MEDIUM**354 H <215 nmol/L

Relative Risk: Optimal <215; Moderate 215-301; High >301. Male Reference Range: 167 to 485 nmol/L; Female Reference Range: 121 to 397 nmol/L.

HDL LARGE 6846 >6729 nmol/L

Relative Risk: Optimal >6729; Moderate 6729-5353; High <5353. Male Reference Range: 4334 to 10815 nmol/L; Female Reference Range: 5038 to 17886 nmol/L.

LDL PATTERN <u>B</u> A A Pattern <sup>Z4M</sup>

Relative Risk: Optimal Pattern A; High Pattern B. Reference Range: Pattern A.

LDL PEAK SIZE  $\frac{217.2}{1}$  L >222.9 Angstrom This test was developed and its analytical performance

characteristics have been determined by Quest Diagnostics



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843 STATUS: Final

Source: Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

**Lab Ref #:** 773650

ORDERING PHYSICIAN:

# Joshua A Emdur, D.O.

600 Congress Avenue

<5.0 calc

<130 mg/dL (calc)

Floor 14

Austin, TX, 78701

Test In Range Out Of Range Reference Range Lab

Cardiometabolic Center of Excellence at Cleveland HeartLab.

It has not been cleared or approved by the U.S. Food and

Drug Administration. This assay has been validated pursuant
to the CLIA regulations and is used for clinical purposes.

Relative Risk: Optimal >222.9; Moderate 222.9-217.4; High <217.4. Male and Female Reference Range: 216 to 234.3
Angstrom. Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on an adult U.S. reference population plus two large cohort study populations. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB.2009;29:1975. For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ134 (This

CARDIO IQ(R) LIPID PANEL Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC CHOLESTEROL, TOTAL 172 <200 mg/dL 74M HDL CHOLESTEROL 63 >39 mg/dL Z4M **TRIGLYCERIDES** 63 <150 mg/dL 74M LDL-CHOLESTEROL 94 <100 mg/dL (calc) 74M

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with >= 2 CHD risk factors.

LDL-C is now calculated using the Martin-Hopkins

calculation, which is a validated novel method providing

better accuracy than the Friedewald equation in the

link is being provided for informational/educational

estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19):

2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)

LDL-C is now calculated using the Martin-Hopkins

calculation, which is a validated novel method providing

better accuracy than the Friedewald equation in the

estimation of LDL-C.

purposes only.)

Martin SS et al. JAMA. 2013;310(19): 2061-2068

(http://education.QuestDiagnostics.com/fag/FAQ164)

CHOL/HDLC RATIO 2.7 NON HDL CHOLESTEROL 109

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70

mg/dL) is considered a therapeutic option.

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic

option.

Enhanced PDF Report SZ983211Q-1 Collected: 11/06/2024 03:32 PM UTC Received: 11/06/2024 03:34 PM UTC

Enhanced PDF Report SZ983211Q-Enhanced PDF Report SZ983211Q-1.pdf [See Appendix 1 for details]



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com

The contents of this document and/or fax transmission are intended only for the use of the individual or entity to which they are addressed and may contain information that is legally privileged, confidential and exempt from disclosure, including protected health information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. If you have received or obtained this document or fax transmission in error, please notify the original sender or contact Health Gorilla Inc. at 1-844-446-7455 immediately by telephone or by email at privacy@healthgorilla.com and delete this document immediately.

Z4M

## Ofer Yehudai

Phone (H): (833) 753-1851 DOB: 02/11/1981 Gender: Male Age: 43 Patient ID: 35049843

Test

STATUS: Final

Source: Quest

Time Reported: 11/15/2024 04:15 AM

UTC

**Received:** 11/15/2024 04:19 AM

UTC

Accession SZ983211Q

Number:

Lab Ref #: 773650 In Range ORDERING PHYSICIAN:

# Joshua A Emdur,

Reference Range

Lab

600 Congress Avenue

Floor 14

**Out Of Range** 

Austin, TX, 78701

1		
UL	Quest Diagnostics-Sacramento - Northgate. 3714 Northgate Blvd, Sacramento, CA 95834-1617	Dir: Shirley Y Shen
EN	Quest Diagnostics-West Hills. 8401 Fallbrook Ave, West Hills, CA 91304-3226	Dir: Thomas J McDonald
EZ	Quest Diagnostics/Nichols SJC-San Juan Capistrano,. 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042	Dir: Irina Maramica MD,PhD,MBA
Z3E	MedFusion-MedFusion. 2501 South State Highway 121, Suite 1100, Lewisville, TX 75067-8188	Dir: Ithiel James L Frame MD,PhD
Z4M	Cleveland HeartLab IncCleveland HeartLab Inc 6701 Carnegie Ave, Suite 500, Cleveland, OH 44103-4623	Dir: Sami Albeiroti PhD,DABCC

#### Range Flags Legend: L - Below low normal; H - Above high normal; A - Abnormal;



Printed from Health Gorilla Secure Clinical Network. Copyright © 2024 Health Gorilla Inc. https://www.healthgorilla.com





Patient Information	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Requisition: 0049494	Client #: 73917267 MAIL992 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Phone: 833.753.1851 Patient ID: 35049843 Health ID: 8573035612986618	Lab Ref #: 773650  Collected: 11/06/2024 / 07:32 PST Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	FUNCTION HEALTH INC 600 CONGRESS AVE FL 14 AUSTIN, TX 78701-3263

In Range	Out Of Range	Reference Range	Lab
			$\mathtt{UL}$
E 2		50-190 mag/dI	
-			
320	16 L	<u> </u>	
160		, ,	UL
61		nmol/L	EN
	Reference I	Range <75	
	Risk:		
		<75	
	Moderate	75-125	
	High	>125	
	Cardiouaga	llar ovent rick gategory	
		9 1	
	2017;69:69:	2-711.	
			$\mathtt{UL}$
	_	mg/dL	
	_		
	52 320 160 61 0.5 Reference	52 320  16 L  160 61  Reference H  Risk: Optimal Moderate High  Cardiovascu cut points are based of 2017;69:692	52 320

Not established

The ADA defines abnormalities in albumin excretion as follows:

Albuminuria Category Result (mg/g creatinine)

Normal to Mildly increased < 30 30-299 Moderately increased > OR = 300Severely increased

The ADA recommends that at least two of three specimens collected within a 3-6 month period be abnormal before considering a patient to be

within a diagnostic category. HS CRP <0.2 UL mg/L

SPECIMEN: SZ983211Q

Reference Range Optimal <1.0

Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.

For ages >17 Years:

hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0 - 3.0Average relative cardiovascular risk. 3.1 - 10.0Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary

to infection or inflammation.

>10.0 Persistent elevation, upon retesting, may be associated with infection and





Patient Information	Specimen Informa	tion	<b>Client Information</b>	
YEHUDAI, OFER	Collected: 11/06	3211Q 5/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA	
DOB: 02/11/1981 AGE: 43		7/2024 / 00:58 PST		
Gender: M	Reported: 11/14	/2024 / 20:15 PST		
Patient ID: 35049843				
Health ID: 8573035612986618				
Test Name inflammation.	In Range	Out Of Range	Reference Range	Lab
Pearson TA, Mensah GA, Alex of inflammation and cardiov application to clinical and A statement for healthcare Centers for Disease Control American Heart Association	vascular diseas d public health professionals L and Preventic	se: n practice: from the on and the		
499-511. APOLIPOPROTEIN B	85		mq/dL	EN
AFODIFOFROIEIN B	03	Reference Ran	_	1714
		Risk Category Optimal Moderate High	<pre>&lt;90 90-119 &gt; or = 120</pre>	
		cut points (o are based on Association r TA et al. J o 9: 129-169 an	r event risk category ptimal, moderate, high) National Lipid ecommendations-Jacobson f Clin Lipid. 2015; d Jellinger PS et al. 2017;23(Suppl 2):1-87.	
COMPREHENSIVE METABOLIC				UL
PANEL	99		CF 00	
GLUCOSE	99		65-99 mg/dL	
		Fas	ting reference interval	
IIDEA NITROCENI (DIINI)	25		7-25 mg/dL	
UREA NITROGEN (BUN) CREATININE	1.02		0.60-1.29 mg/dL	
EGFR	94		> OR = 60  mL/min/1.73m2	
BUN/CREATININE RATIO	SEE NOTE:	tad. DIM and G	6-22 (calc)	
		erted: BUN and Cr e range.	reatinine are within	
SODIUM	140		135-146 mmol/L	
POTASSIUM	4.5		3.5-5.3 mmol/L	
CHLORIDE	103 31		98-110 mmol/L	
CARBON DIOXIDE CALCIUM	9.3		20-32 mmol/L 8.6-10.3 mg/dL	
PROTEIN, TOTAL	6.9		6.1-8.1 g/dL	
ALBUMIN	4.6		3.6-5.1 g/dL	
GLOBULIN	2.3		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	2.0		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.4		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	44 24		36-130 U/L 10-40 U/L	
AST ALT	25		9-46 U/L	
HEMOGLOBIN A1c	5.5		<5.7 % of total Hgb	UL
For the purpose of screening		sence of		~ <b>_</b>
diabetes:	_			
<5.7% Consistent with 5.7-6.4% Consistent with		of diabetes sk for diabetes		

SPECIMEN: SZ983211Q





<b>Patient Information</b>	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Collected: 11/06/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Patient ID: 35049843 Health ID: 8573035612986618	Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	

Test Name In Range Out Of Range Reference Range Lab

(prediabetes)

> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

URIC ACID	5.0		4.0-8.0 mg/dL	UL
Therapeutic target f	or gout patients: <6.	.0 mg/dL		
mari	2 12		0 40 4 50 /	
TSH	2.13		0.40-4.50 mIU/L	$\mathtt{UL}$
T4, FREE	1.1		0.8-1.8 ng/dL	$\mathtt{UL}$
T3, FREE	3.3		2.3-4.2 pg/mL	UL
CBC (INCLUDES DIFF/PLT)			13,	ŪL
WHITE BLOOD CELL COUNT	5.3		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	4.62		4.20-5.80 Million/uL	
HEMOGLOBIN		12.7 L	13.2-17.1 g/dL	
HEMATOCRIT	39.9		38.5-50.0 %	
MCV	86.4		80.0-100.0 fL	
MCH	27.5		27.0-33.0 pg	
MCHC		31.8 L	32.0-36.0 g/dL	
For adults, a slight	decrease in the cald	culated MCHC	_	

For adults, a slight decrease in the calculated MCHC value (in the range of 30 to  $32~\mathrm{g/dL}$ ) is most likely not clinically significant; however, it should be interpreted with caution in correlation with other red cell parameters and the patient's clinical condition.

condition.		
RDW	12.7	11.0-15.0 %
PLATELET COUNT	184	140-400 Thousand/uL
MPV	10.6	7.5-12.5 fL
ABSOLUTE NEUTROPHILS	2873	1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES	1701	850-3900 cells/uL
ABSOLUTE MONOCYTES	429	200-950 cells/uL
ABSOLUTE EOSINOPHILS	249	15-500 cells/uL
ABSOLUTE BASOPHILS	48	0-200 cells/uL
NEUTROPHILS	54.2	%
LYMPHOCYTES	32.1	%
MONOCYTES	8.1	%
EOSINOPHILS	4.7	%
BASOPHILS	0.9	%
JRINALYSIS, COMPLETE		

SPECIMEN: SZ983211Q

COLOR YELLOW YELLOW APPEARANCE CLEAR CLEAR SPECIFIC GRAVITY 1.021 1.001-1.035 6.0 5.0-8.0 GLUCOSE NEGATIVE NEGATIVE BILIRUBIN NEGATIVE NEGATIVE KETONES NEGATIVE NEGATIVE

UL





Patient Information	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Collected: 11/06/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Patient ID: 35049843 Health ID: 8573035612986618	Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	

Test Name	In Range	Out Of Range	Reference Range	Lab
OCCULT BLOOD	NEGATIVE		NEGATIVE	
PROTEIN	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	
WBC	NONE SEEN		< OR = 5 / HPF	
RBC	NONE SEEN		< OR = 2 / HPF	
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 / HPF	
BACTERIA	NONE SEEN		NONE SEEN /HPF	
HYALINE CAST	NONE SEEN		NONE SEEN /LPF	
This urine was analyzed for t	he presence o	of WBC,		
RBC, bacteria, casts, and oth	er formed ele	ements.		
Only those elements seen were	reported.			

CORTISOL, TOTAL, LC/MS

13.8

mcg/dL

EZ

Adult Reference Ranges for Cortisol, Total:

 $8-10 \text{ AM} \quad 4.6-20.6 \text{ mcg/dL}$ 4-6 PM 1.8-13.6 mcg/dL

Cortisol Response to ACTH Peak >20.0 mcg/dL

Peak >16.0 mcg/dL after IM injection

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

INSULIN 3.8 EN uIU/mL Reference Range < or = 18.4

Risk:

Optimal < or = 18.4Moderate NA High >18.4

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Insulin Reference Interval studies performed at Quest Diagnostics

in 2022.

MERCURY, BLOOD <OR=10 mcg/L ΕN

See Endnote 1

ABO GROUP AND RH TYPE UL

SPECIMEN: SZ983211Q

ABO GROUP

RH TYPE RH(D) POSITIVE

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ111 (This link is being provided for informational/ educational purposes only.)





Patient Information	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Collected: 11/06/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Patient ID: 35049843 Health ID: 8573035612986618	Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	

Test NameIn RangeOut Of RangeReference RangeLabMAGNESIUM, RBC4.94.0-6.4 mg/dLZ3E

(Note)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

MDF med fusion 2501 South State Highway 121,Suite 1100 Lewisville TX 75067 972-966-7300 Ithiel James L. Frame, MD, PhD

#### Endnote 1

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

SPECIMEN: SZ983211Q





Patient Information	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Collected: 11/06/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Patient ID: 35049843 Health ID: 8573035612986618	Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	

#### Endocrinology

Endocrinology				
Test Nam	пе	Result	Reference Range	Lab
VITAMIN D,25-OH,TOTAL,IA		30	30-100 ng/mL	UL
Vitamin D Status	25-OH Vitamin	D:		
Deficiency: Insufficiency: Optimal: For 25-OH Vitamin D testing or QuestAssureD(TM) 25-OH VIT		mL mL itation and patients for whom q	uantitation of D2 and D3 fractions is requir 8 (patients >2yrs).	red, the
For additional information, please purposes only.)	e refer to http://education.Qu	uestDiagnostics.com/faq/FAQ1	99 (This link is being provided for informat	ional/ educational
Physician Comments:				

SPECIMEN: SZ983211Q





<b>Patient Information</b>	Specimen Information	Client Information
YEHUDAI, OFER	Specimen: SZ983211Q Collected: 11/06/2024 / 07:32 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 02/11/1981 AGE: 43 Gender: M Patient ID: 35049843 Health ID: 8573035612986618	Received: 11/07/2024 / 00:58 PST Reported: 11/14/2024 / 20:15 PST	

			Cardio I	$\mathbf{Q}^{ ext{ ext{ ext{ ext{ ext{ ext{ ext{ ext$			
	Cu	rrent	Risk/Reference Interval				Historical
Test Name		t & Risk	Optimal	Moderate	High	Units -	Result & Risk
	Optimal	Non-Optimal					
LIPID PANEL							
CHOLESTEROL, TOTAL	172		<200	N/A	>=200	mg/dL	
HDL CHOLESTEROL	63		>=40	N/A	<40	mg/dL	
TRIGLYCERIDES	63		<150	150-199	>=200	mg/dL	
LDL-CHOLESTEROL	94		<100	100-129	>129	mg/dL	
				100 120	7 120	(calc)	
CHOL/HDLC RATIO	2.7		<=3.5	3.6-5.0	>5.0	calc	
NON-HDL CHOLESTEROL	109		<130	130-189	>=190	mg/dL	
THOM TIDE OFFICE OF TEXTS	103				>=150	(calc)	
LIPOPROTEIN FRACTIO	NATION, IC	ON MOBILIT					
LDL PARTICLE NUMBER		1643	<1138	1138-1409	>1409	nmol/L	
LDL SMALL		316	<142	142-219	>219	nmol/L	
LDL MEDIUM		354	<215	215-301	>301	nmol/L	
HDL LARGE	6846		>6729	6729-5353	<5353	nmol/L	
LDL PATTERN		В	А	N/A	В	Pattern	
LDL PEAK SIZE		217.2	>222.9	222.9-217.4	<217.4	Angstrom	

For details on reference ranges please refer to the reference range/comment section of the report.

**Medical Information For Healthcare Providers:** If you have questions about any of the tests in our Cardio IQ offering, please call Client Services at our Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence. They can be reached at 866.358.9828, option 1 to arrange a consult with our clinical education team.





Patient Information	<b>Specimen Information</b>	<b>Client Information</b>						
YEHUDAI, OFER	Specimen: SZ983211Q	Client #: 73917267						
	Collected: 11/06/2024 / 07:32 PST	EMDUR, JOSHUA						
DOB: 02/11/1981 AGE: 43	Received: 11/07/2024 / 00:58 PST							
Gender: M	Reported: 11/14/2024 / 20:15 PST							
Patient ID: 35049843								
Health ID: 8573035612986618								
Reference Range/Comments								

Analyte Name	In Range	Out Range	Reference Range	Lab			
LDL MEDIUM		354	<215 nmol/L	Z4M			
Relative Risk: Optimal <215; Moderate 215-301; High >301. Male Reference Range: 167 to 485 nmol/L; Female Reference Range: 121 to 397 nmol/L.							
LDL PARTICLE NUMBER		1643	<1138 nmol/L	Z4M			
Relative Risk: Optimal <1138; Moderate 1138	8-1409; High >1409. Male and	d Female Reference I	Range: 1016 to 2185 nmol/L.	J			
LDL PATTERN		В	A Pattern	Z4M			
Relative Risk: Optimal Pattern A; High Pattern	n B. Reference Range: Patter	rn A.	1				
LDL PEAK SIZE		217.2	>222.9 Angstrom	Z4M			
used for clinical purposes. Relative Risk: Opticardiovascular event risk category cut points	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are	Administration. This a 217.4; High <217.4. based on an adult U	assay has been validated pursuant to the CLIA regi Male and Female Reference Range: 216 to 234.3 A .S. reference population plus two large cohort study	ulations and is Angstrom. Adult populations.			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opticardiovascular event risk category cut points	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is	Administration. This a 217.4; High <217.4. based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA reging Male and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional information	ulations and is Angstrom. Adult populations.			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opti cardiovascular event risk category cut points (Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to	Administration. This 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA regingles and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort studyet al. ATVB.2009;29:1975. For additional informaticational purposes only.)	ulations and is angstrom. Adult oppulations. In, please refer to http			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opti cardiovascular event risk category cut points (Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to	Administration. This 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA regimale and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional informatic cational purposes only.)  <142 nmol/L	ulations and is angstrom. Adult oppulations. In, please refer to http			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opticardiovascular event risk category cut points. Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL  Relative Risk: Optimal <142; Moderate 142-2	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to 219; High >219. Male Referen	Administration. This 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA regimale and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional informaticational purposes only.)  <142 nmol/L  I nmol/L; Female Reference Range: 115 to 386 nm	ulations and is angstrom. Adult populations. on, please refer to http.  Z4M  ol/L.			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opti cardiovascular event risk category cut points : Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL  Relative Risk: Optimal <142; Moderate 142-2  CHOL/HDLC RATIO	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to the cardiovascular events at 219; High >219. Male Referen 2.7	Administration. This 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA regimale and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional informatic cational purposes only.)  <142 nmol/L  Inmol/L; Female Reference Range: 115 to 386 nm  <5.0 calc	ulations and is Angstrom. Adult oppulations. In, please refer to http  Z4M  OI/L.  Z4M			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opticardiovascular event risk category cut points (Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL  Relative Risk: Optimal <142; Moderate 142-2  CHOL/HDLC RATIO  CHOLESTEROL, TOTAL  HDL CHOLESTEROL	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to 219; High >219. Male Referen 2.7	Administration. This 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ	assay has been validated pursuant to the CLIA regimale and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional informaticational purposes only.)  <142 nmol/L  I nmol/L; Female Reference Range: 115 to 386 nm  <5.0 calc  <200 mg/dL	ulations and is Angstrom. Adult Populations. In, please refer to http  Z4M  ol/L.  Z4M  Z4M			
HeartLab. It has not been cleared or approved used for clinical purposes. Relative Risk: Opti cardiovascular event risk category cut points : Association between lipoprotein subfractions education.QuestDiagnostics.com/faq/FAQ134LDL SMALL  Relative Risk: Optimal <142; Moderate 142-2  CHOL/HDLC RATIO  CHOLESTEROL, TOTAL  HDL CHOLESTEROL  HDL LARGE	d by the U.S. Food and Drug imal >222.9; Moderate 222.9- (optimal, moderate, high) are and cardiovascular events is 4 (This link is being provided to 2.19; High >219. Male Referen 2.7 172 63 6846	Administration. This a 217.4; High <217.4. I based on an adult U based on Musunuru for informational/educ 316  ce Range: 123 to 441	assay has been validated pursuant to the CLIA regimale and Female Reference Range: 216 to 234.3 A.S. reference population plus two large cohort study et al. ATVB.2009;29:1975. For additional informatic actional purposes only.)  <142 nmol/L  Inmol/L; Female Reference Range: 115 to 386 nm  <5.0 calc  <200 mg/dL  >39 mg/dL	ulations and is Angstrom. Adult Populations. In, please refer to http:  Z4M  OI/L.  Z4M  Z4M  Z4M  Z4M  Z4M			

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with >= 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) NON HDL CHOLESTEROL <130 mg/dL (calc) 74M

	NOTTIBL OF OLICEOTEROE	100		Troo mg/all (balo)	
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.					
	TRIGLYCERIDES	63		<150 mg/dL	Z4M

SPECIMEN: SZ983211Q

#### **PERFORMING SITE:**

- QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: THOMAS MCDONALD, MD, CLIA: 05D0642827
- ΕZ QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA, MD, PHD, MBA, CLIA: 05D0643352
- UL QUEST DIAGNOSTICS SACRAMENTO, 3714 NORTHGATE BLVD, SACRAMENTO, CA 95834-1617 Laboratory Director: SHIRLEY Y SHEN, MD, CLIA: 05D0644209 Z3E
- MEDFUSION, 2501 SOUTH STATE HIGHWAY 121 SUITE 1100, LEWISVILLE, TX 75067-8188 Laboratory Director: ITHIEL J FRAME,MD,PHD, CLIA: 45D2004217 CLEVELAND HEARTLAB INC, 6701 CARNEGIE AVENUE SUITE 500, CLEVELAND, OH 44103-4623 Laboratory Director: SAMI ALBEIROTI,PHD,DABCC, CLIA: 36D1032987 Z4M